$0.19
−20.88%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$0.20
From 52W high−100.00%
Volume1.14M
Market cap$209159.79
P/E (TTM)—
P/S (TTM)0.0x
Div yield—
Key dataOct 19, 2026
Open
$0.20
From 52W high
−100.00%
Volume
1.14M
Market cap
$209159.79
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
4.6x
P/E (TTM)
—
RSI (14)
15.2
MomentumView details →
1D Return
−20.88%
YTD Return
−100.00%
SummaryUpdated Jun 1, 2026
Conduit Pharmaceuticals Inc. (NASDAQ:CDT) is a clinical-stage specialty biopharmaceutical company founded in 2019 and headquartered in San Diego, California. The company went public in March 2022 and operates as a subsidiary of Corvus Capital Limited. Conduit focuses on developing treatments for unmet medical needs in autoimmune diseases and male reproductive health, with a pipeline centered around two main drug candidates targeting conditions such as Hashimoto's thyroiditis and idiopathic male infertility.
Similar companies
Latest newsMore news →
EQUITY BANCSHARES INC announced that its board fixed October 30, 2026, as the record date for a two-for-one subdivision of its equity shares, reducing face value from Rs. 10 to Rs. 5 per share.3d agoSarborg Limited announced an intellectual-property patent filing covering novel solid forms of a respiratory medicine.6d ago